Movers and Shakers Alert as CMBM Rockets Today

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  29 Oct 2025
 

•   AVTR  
   
  -6.54%
•   CMBM  
   
  +27.16%
•   FI  
   
  -2.75%
•   FLS  
   
  -0.17%
•   GIC  
   
  -2.11%

$CMBM surged after announcing a game-changing integration with Starlink that positions the networking company squarely in the enterprise connectivity space. Cambium Networks revealed that its Network Service Edge and cnMaestro platforms will now bring centralized management, multi-WAN optimization, and enhanced security to Starlink deployments. The stock exploded on volume exceeding 452 million shares, nearly 1,800 times its average daily turnover, as traders recognized the strategic value of becoming a key infrastructure partner to SpaceX rapidly expanding Starlink network.

$PPBT jumped after Purple Biotech announced a crucial manufacturing milestone for IM1240, a tri-specific antibody developed through its proprietary CAPTN-3 platform. The achievement of commercially viable yield levels represents a significant de-risking event for the biotech, as manufacturing scalability often determines whether promising drug candidates can transition from laboratory success to market reality. Volume surged to 406 million shares against a typical daily average of just 253,000, reflecting the market recognition that Purple Biotech has positioned its program competitively for future development partnerships.

$PUMP revealed an earnings surprise of nearly 82% despite the company posting a loss for the period. ProPetro Holding also delivered revenue that exceeded estimates by over 14%, demonstrating operational execution that surpassed Wall Street's expectations even in a challenging environment for oilfield services. Volume reached 22 million shares, more than six times the daily average, as the strong earnings beat suggests ProPetro may be capturing market share or benefiting from improving conditions in hydraulic fracturing services.

$FLS climbed 31% ahead of its third-quarter earnings conference call scheduled for mid-morning, with Flowserve Corporation drawing interest from traders positioning ahead of the industrial equipment manufacturer's results. Volume of 9.57 million shares represented nearly five times the normal daily activity, indicating substantial institutional participation in the pre-earnings move. The rally suggests optimism about potential strength in the company's pump and valve businesses, which serve energy, chemical, and water infrastructure markets that have shown resilience despite broader economic uncertainties.

$ZEUS Olympic Steel declared a $0.16 dividend, rewarding shareholders while the metals service center operator continues to navigate fluctuating demand conditions in its end markets. Volume of 950,000 shares represented roughly 14 times the typical daily turnover, as income-focused investors responded positively to the distribution announcement. The dividend declaration signals management confidence in cash flow generation and balance sheet stability, important considerations for cyclical industrial companies facing uncertain economic conditions ahead.

$GIC dropped 18% as she faced notable ETF outflows, with significant redemption activity detected in the iShares Global Industrials ETF that holds the stock among its positions. Volume of 306,000 shares represented more than three times normal levels, as passive selling pressure from ETF rebalancing created technical headwinds regardless of the company's fundamental outlook. These mechanically driven declines often create temporary dislocations that fundamental investors monitor for potential entry points once the selling subsides.

$AVTR collapsed after Avantor posted a third-quarter net loss driven by impairment charges, with the life sciences supplier missing both earnings and revenue estimates. The company reported non-GAAP EPS of $0.22, missing by a penny, while revenue of $1.62 billion fell short by $30 million, representing negative surprises of 4.35% and 1.56% respectively. Volume surged to 31 million shares, nearly three times average levels, as the stock extended losses for a fifth consecutive session, raising concerns about challenges in serving life sciences and technology industry customers.

$NLSP the stock dropped for a fifth straight day on volume of 1.38 million shares, slightly above its average daily turnover of 1.23 million. The persistent selling pressure without a specific news catalyst suggests ongoing concerns about the company's fundamental outlook or technical breakdown triggering stop-loss orders and momentum-based selling. Extended losing streaks often exhaust sellers eventually, but the lack of stabilization signals that negative sentiment remains firmly entrenched among the shareholder base.

$FI Fiserv reported third-quarter results that badly missed expectations and management slashed forward guidance. The financial technology giant posted non-GAAP earnings of $2.04 per share, missing estimates by 61 cents, while revenue of $4.92 billion fell short by $430 million, representing misses of roughly 23% and 8% respectively. Volume exploded to 94 million shares, more than 20 times the average, as the company simultaneously announced a leadership shakeup and plans to transfer its listing from the NYSE to Nasdaq under the new ticker symbol FISV, with technical indicators showing the stock deeply oversold on what analysts are calling its worst day ever.

$VRNS collapsed nearly 49% as Varonis Systems delivered weak third-quarter guidance attributed to softness in federal government spending. The cybersecurity company's sharp decline on volume of 26 million shares, roughly 19 times normal levels, reflects concerns about a key growth driver faltering at a time when the broader security software sector faces increasing competitive pressures. Federal contracts often represent high-margin, recurring revenue for enterprise software companies, and weakness in this segment raises questions about whether Varonis can maintain growth rates that justify its valuation.

View All Headlines